• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

用碘-131治疗格雷夫斯病时给药活度的确定:一种简化剂量测定程序的建议。

Determination of administered activities for the treatment of Graves' disease with iodine-131: Proposition of a simplified dosimetric procedure.

作者信息

Soli Idrissa Adamou, Issoufou Djibrillou Moussa, Rahabi Skander, Ali Ada, Adehossi Eric, Bouyoucef Salah Eddine

机构信息

Department of Nuclear Medicine Radio-Isotopes Institute, Abdou Moumouni University, Niamey, Niger.

Faculty of Medicine, Abdou Moumouni University, Niamey, Niger.

出版信息

World J Nucl Med. 2021 Aug 20;20(3):222-227. doi: 10.4103/wjnm.WJNM_47_20. eCollection 2021 Jul-Sep.

DOI:10.4103/wjnm.WJNM_47_20
PMID:34703389
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC8488895/
Abstract

This prospective study included 35 patients suffering from Graves' disease (GD) clinically and biologically confirmed by endocrinologists, sent to the nuclear medicine department of CHU de Bab El Oued, Algiers for iodine-131 therapy. CHU de Bab El Oued is a tertiary hospital located in the center of the capital Algiers. The aim of this study is to propose a simplified dosimetric procedure which will initiate iodine-131 therapy of GD in particular and hyperthyroidism in general in Niger. The determination of the maximum uptake was performed with a Biodex external probe at 2 h, 4 h, and 24 h after the administration of 3 MBq of liquid iodine-131. The iodine-131 activities were determined using the Marinelli formula with a predefined effective half-life (T) of 5 days and subsequently extrapolated half-life with kaleidagraph software. The statistical analysis was performed using an excel sheet and analyzed using the software package Statistica 10 (stat Soft, Tulsa, USA). the male:female gender ratio was1:4.5 and the mean age was 42.56 years (±7.14). The body mass index was within normal range with a value of 25.25 kg(±0.42) and the mean average thyroid mass was equal to 24.05 (±10.53) g. The mean uptake value at 24 h was 43.24% (±17.68%) meanwhile the maximum uptake value was 46.28 (±21.13%). The estimated effective half-life (T) was 5.44 days (±1.96) days which were different from the predefined T of 5 days. The mean activity determined with fixed T and 24 h uptake was 244.45 (±109.2) MBq and the mean activity calculated with both extrapolated T and maximum uptake was 452.22 (±381.9) MBq. Empirical determination of activity in the treatment of GD gives higher activities (1.5 times) to patients than dosimetric methods based on the determination of extrapolated effective half-life.

摘要

这项前瞻性研究纳入了35例经内分泌科医生临床和生物学确诊为格雷夫斯病(GD)的患者,他们被送往阿尔及尔巴卜勒乌德大学医院核医学科接受碘-131治疗。巴卜勒乌德大学医院是位于首都阿尔及尔市中心的一家三级医院。本研究的目的是提出一种简化的剂量测定程序,该程序将在尼日尔启动对GD尤其是一般甲状腺功能亢进症的碘-131治疗。在给予3MBq液态碘-131后2小时、4小时和24小时,使用Biodex外部探头测定最大摄取量。使用Marinelli公式,在预定义的有效半衰期(T)为5天的情况下测定碘-131活度,随后使用kaleidagraph软件外推半衰期。使用电子表格进行统计分析,并使用Statistica 10软件包(美国塔尔萨stat Soft公司)进行分析。男女比例为1:4.5,平均年龄为42.56岁(±7.14)。体重指数在正常范围内,值为25.25kg(±0.42),平均甲状腺质量等于24.05(±10.53)g。24小时时的平均摄取值为43.24%(±17.68%),同时最大摄取值为46.28(±21.13%)。估计的有效半衰期(T)为5.44天(±1.96)天,与预定义的5天T不同。用固定T和24小时摄取量测定的平均活度为244.45(±109.2)MBq,用外推T和最大摄取量计算的平均活度为452.22(±381.9)MBq。GD治疗中活度的经验性测定比基于外推有效半衰期测定的剂量测定方法给患者的活度更高(1.5倍)。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/7e9d/8488895/65aabfe86713/WJNM-20-222-g009.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/7e9d/8488895/b276b0ef795b/WJNM-20-222-g007.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/7e9d/8488895/06c12c8c7b80/WJNM-20-222-g008.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/7e9d/8488895/65aabfe86713/WJNM-20-222-g009.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/7e9d/8488895/b276b0ef795b/WJNM-20-222-g007.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/7e9d/8488895/06c12c8c7b80/WJNM-20-222-g008.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/7e9d/8488895/65aabfe86713/WJNM-20-222-g009.jpg

相似文献

1
Determination of administered activities for the treatment of Graves' disease with iodine-131: Proposition of a simplified dosimetric procedure.用碘-131治疗格雷夫斯病时给药活度的确定:一种简化剂量测定程序的建议。
World J Nucl Med. 2021 Aug 20;20(3):222-227. doi: 10.4103/wjnm.WJNM_47_20. eCollection 2021 Jul-Sep.
2
[Radioiodine treatment of hyperthyroidism using a simplified dosimetric approach. Clinical results].[采用简化剂量测定法进行放射性碘治疗甲状腺功能亢进症。临床结果]
Radiol Med. 2000 Dec;100(6):480-3.
3
Iodine-131 treatment of hyperthyroidism: significance of effective half-life measurements.碘-131治疗甲状腺功能亢进症:有效半衰期测量的意义
J Nucl Med. 1996 Feb;37(2):228-32.
4
Correlation of radioiodine doses for 6-hr and 24-hour iodine-131 thyroid uptake values for Graves' hyperthyroidism.格雷夫斯甲亢 6 小时和 24 小时碘-131 甲状腺摄取值的放射性碘剂量的相关性。
Endocr J. 2019 Dec 25;66(12):1047-1052. doi: 10.1507/endocrj.EJ19-0199. Epub 2019 Aug 7.
5
Follow-up on thyroidal uptake after radioiodine therapy: how robust is the peri-therapeutic dosimetry?放射性碘治疗后甲状腺摄取的随访:治疗期剂量学的稳健性如何?
Z Med Phys. 2011 Dec;21(4):258-65. doi: 10.1016/j.zemedi.2011.04.006. Epub 2011 Jun 29.
6
Determining thyroid (131)I effective half-life for the treatment planning of Graves' disease.测定甲状腺 (131)I 有效半衰期以制定 Graves 病的治疗计划。
Med Phys. 2013 Feb;40(2):022502. doi: 10.1118/1.4788660.
7
Radioiodine therapy of benign thyroid disorders: what are the effective thyroidal half-life and uptake of 131I?良性甲状腺疾病的放射性碘治疗:131I的有效甲状腺半衰期及摄取率是多少?
Nucl Med Commun. 2010 Mar;31(3):201-5. doi: 10.1097/MNM.0b013e328333d303.
8
Prognostic factor analysis in 325 patients with Graves' disease treated with radioiodine therapy.325例接受放射性碘治疗的格雷夫斯病患者的预后因素分析。
Nucl Med Commun. 2018 Jan;39(1):16-21. doi: 10.1097/MNM.0000000000000770.
9
Radiation Safety Precautions in (131)I Therapy of Graves' Disease Based on Actual Biokinetic Measurements.基于实际生物动力学测量的格雷夫斯病(131)I治疗中的辐射安全预防措施。
J Clin Endocrinol Metab. 2015 Aug;100(8):2934-41. doi: 10.1210/jc.2015-1682. Epub 2015 Jun 5.
10
The impact of different computational assumptions in I dosimetry for hyperthyroidism therapy.不同计算假设在甲状腺功能亢进症治疗剂量测定中的影响。
Med Phys. 2020 Nov;47(11):5810-5816. doi: 10.1002/mp.14478. Epub 2020 Oct 8.

本文引用的文献

1
Dosimetry-based treatment for Graves' disease.基于剂量测定法的格雷夫斯病治疗
Nucl Med Commun. 2018 Jun;39(6):486-492. doi: 10.1097/MNM.0000000000000826.
2
Prediction of thyroidal I effective half-life in patients with Graves' disease.格雷夫斯病患者甲状腺I有效半衰期的预测
Oncotarget. 2017 Sep 12;8(46):80934-80940. doi: 10.18632/oncotarget.20849. eCollection 2017 Oct 6.
3
Determining thyroid (131)I effective half-life for the treatment planning of Graves' disease.测定甲状腺 (131)I 有效半衰期以制定 Graves 病的治疗计划。
Med Phys. 2013 Feb;40(2):022502. doi: 10.1118/1.4788660.
4
The SNMMI practice guideline for therapy of thyroid disease with 131I 3.0.核医学与分子影像学会(SNMMI)131I治疗甲状腺疾病的实践指南3.0版
J Nucl Med. 2012 Oct;53(10):1633-51. doi: 10.2967/jnumed.112.105148. Epub 2012 Jul 11.
5
Investigation of biokinetics of radioiodine with a population kinetics approach.
Radiat Prot Dosimetry. 2010 Apr-May;139(1-3):232-5. doi: 10.1093/rpd/ncq054. Epub 2010 Feb 19.
6
Clinical practice. Graves' disease.临床实践。格雷夫斯病。
N Engl J Med. 2008 Jun 12;358(24):2594-605. doi: 10.1056/NEJMcp0801880.
7
Verification of the agreement of two dosimetric methods with radioiodine therapy in hyperthyroid patients.两种剂量测定方法与甲状腺功能亢进患者放射性碘治疗一致性的验证。
Med Phys. 2006 Aug;33(8):2860-7. doi: 10.1118/1.2210564.
8
Tissue-specific dosimetry for radioiodine therapy of the autonomous thyroid nodule.
Med Phys. 2003 May;30(5):791-8. doi: 10.1118/1.1567270.
9
Iodine-131 treatment of hyperthyroidism: significance of effective half-life measurements.碘-131治疗甲状腺功能亢进症:有效半衰期测量的意义
J Nucl Med. 1996 Feb;37(2):228-32.
10
Influence of dose selection on absorbed dose profiles in radioiodine treatment of diffuse toxic goiters in patients receiving or not receiving carbimazole.
J Nucl Med. 1993 Mar;34(3):387-93.